colorectal cancer

Latest Headlines

Latest Headlines

Domain Elite makes its first investment in a China-focused operation

Domain Associates' Elite enterprise is making its first investment in a China-focused company. The venture capital firm will sink $6.5 million into SMART Medical Systems, an Israeli developer and manufacturer of cost-effective endoscopy and colonoscopy products.

Exact Sciences wins unanimous FDA panel approval for its colon cancer Dx

Exact Sciences won unanimous FDA committee approval for its stool-based cancer diagnostic, moving the company one step closer to receiving full regulatory clearance for the test.

A massive review reaffirms fecal test's place in colon cancer Dx

Scientists continue to push for the development of a more precise, sensitive and cleaner colorectal cancer diagnostic. Now a research team has determined that a simple, at-home test already on the market is highly accurate.

Illumina brings next-generation sequencing to Amgen companion Dx deal

Many new drugs these days are made with companion diagnostic tests in mind, and Amgen's treatment for metastatic colorectal cancer is no different. Illumina has inked a deal to develop a test that screens for patients who'd benefit most from the drug.

Quest unloads colon cancer Dx business as revamp marches on

Quest Diagnostics' ongoing revamp continued this week with news that an Australian company has snatched up its colorectal cancer screening test business. Neither side is commenting on the financial details.

Quintiles looks to biomarkers to speed up cancer trials

Quintiles, the world's largest CRO, has launched a study to determine whether preprofiling cancer patients for key biomarkers can ease trial enrollment and speed drug development.

Amgen basks in EU approval of Bayer/Onyx cancer drug Stivarga

The European Commission has stamped an approval on Stivarga (a.k.a. regorafenib) for aggressive cases of colorectal cancer, marking a regulatory victory for Bayer Healthcare and Onyx Pharmaceuticals ($ONXX). Amgen ($AMGN) benefits, too.

Applied Proteomics bags $28M round to roll out colon cancer test

San Diego's Advanced Proteomics is gearing up to launch its first diagnostic tests, and now the company has $28 million to get it there thanks to a just-closed Series C.

Low levels of a specific protein identify aggressive colorectal cancer

U.K. scientists have zeroed in on a biomarker that could rapidly identify colorectal cancer patients who need aggressive chemotherapy treatment to prevent metastasis. The biomarker also offers a potential new drug target.

Bayer, Raptor reel in endorsements from EMA for new therapies

The European Medicines Agency's experts have backed approval for two drugs that have already gained green lights for the U.S. market.